4552   JCR Pharmaceuticals Co.,Ltd.

04/25/2024 16:00	Notice of Personnel Change
04/25/2024 16:00	Notice Regarding Nomination of a Candidate to the Board of Director
04/22/2024 14:00	JCR Pharmaceuticals Announces Naming Rights Partnership for "Uchibun"
03/19/2024 16:00	JCR Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion
02/28/2024 16:00	JCR Pharmaceuticals Celebrates Rare Disease Day 2024 and Highlights its Commitment to the Rare Disease
02/28/2024 16:00	Notice of Director's Responsibility, Organizational and Personnel Changes
02/09/2024 10:30	[Delayed]Financial Summary Consolidated Financial Results for the Nine Months Ended December 31, 2023 (FY2023)(Japanese standard)
02/06/2024 17:00	[Delayed]FY2023 3rd Quarter Appendix to the Consolidated Financial Summary
01/24/2024 16:00	JCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium 2024
12/20/2023 16:00	JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo
12/20/2023 16:00	JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration
12/20/2023 13:00	Notice of Change in Duties of Directors
12/14/2023 16:00	U.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)
11/28/2023 16:00	[Delayed]FY2023 First-Half Appendix to the Consolidated Financial Summary
11/21/2023 16:00	[Delayed] Financial Summary Consolidated Financial Results for the Six Months ended September 30, 2023 (FY2023) (Japanese standard)
11/07/2023 15:00	AlliedCel Has Acquired a New Pipeline to Promote the Early Social Implementation of Regenerative Medicine Products
11/01/2023 17:00	FY2023 First-Half Results Briefing Session Presentation Material
10/27/2023 10:00	JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA
10/02/2023 11:00	PHC IVD and JCR Announce Upgrade of Melon Nikki Medication Management App for Pediatric Patients Undergoing Growth Hormone Therapy
09/29/2023 16:00	JCR Pharmaceuticals Announces 52-week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with MPS I
09/28/2023 16:00	Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2024
09/28/2023 16:00	MEDIPAL HOLDINGS and JCR Pharmaceuticals Conclude Two Agreements on Mucopolysaccharidosis Type IIIB Treatment
09/11/2023 16:00	[Delayed]Notice Regarding Recognition in the 2nd Hyogo Kobe Women's Empowerment Business (Mimoza Certified Company) Accreditation
09/01/2023 13:00	[Delayed]PHC IVD and JCR Announce GROWJECTOR Duo, a Motorized Digital Injector for Pediatric Patients Undergoing Gorwth Hormone Therapy
08/31/2023 16:00	Notice of Personnel Change
08/31/2023 16:00	Notice regarding Sponsorship for Relay for Life Japan
08/21/2023 13:55	[Delayed]Financial Summary Consolidated Financial Results for the Three Months ended June 30, 2023 (FY2023) (Japanese standard)
07/13/2023 16:00	Notice regarding Finalized Details of issuance of Stock Options as Stock-linked Compensation (Share Subscription Rights)
07/11/2023 16:00	JCR Receives Approval to Start Global Phase I/II Clinical Trial for JR-441 for the Treatment of Mucopolysaccharidosis Type III A (MPS IIIA)
06/26/2023 16:30	JCR receives an Approval for Expanded Indication of Growject in Short Stature due to SHOX-Deficiency
06/21/2023 16:00	Matters Concerning Controlling Shareholders (Affiliated Companies)
06/21/2023 16:00	Notice of Allotment of Stock Options as Stock-linked Compensation (Share Subscription Rights)
06/20/2023 16:00	[Delayed]JCR Receives the 48th Inoue Harushige Prize for Therapeutics for LSDs with an Original BBB Penetrating Technology
06/07/2023 10:30	[Delayed]FY2022 Second-Half Results Briefing Session -Financial Results-
05/31/2023 08:00	Other Matters Subject to Measures for Electronic Provision When Convening the 48th Ordinary General Meeting of Shareholders
05/31/2023 08:00	Notice of Convocation of The 48th Ordinary General Meeting of Shareholders
05/30/2023 11:30	[Delayed]Financial Summary Consolidated Financial Results for the Year ended March 31, 2023 (FY2022) (Japanese Standard)
05/26/2023 17:00	[Delayed] Notice of Issuance of Stock Options as Stock-linked Compensation (Share Subscription Rights)
05/17/2023 17:00	[Delayed]JCR Formulates Midterm Business Plan for FY2023-FY2027
05/11/2023 16:00	FY2022 Second-Half Results Briefing Session - Midterm Business Plan for FY2023 2027 -
05/11/2023 16:00	FY2022 Second-Half Results Briefing Session - Business Highlights -
05/11/2023 16:00	Angelini Pharma and JCR Announce Global Collaboration for the Development and Commercialization of Novel Biologic Therapies in Epilepsy
05/11/2023 16:00	Notice of Distribution of Retained Earnings